View Item 

Show simple item record

In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles

dc.contributor.authorHertz, Daniel L.en_US
dc.contributor.authorSnavely, Anna C.en_US
dc.contributor.authorMcLeod, Howard L.en_US
dc.contributor.authorWalko, Christine M.en_US
dc.contributor.authorIbrahim, Joseph G.en_US
dc.contributor.authorAnderson, Stevenen_US
dc.contributor.authorWeck, Karen E.en_US
dc.contributor.authorMagrinat, Gustaven_US
dc.contributor.authorOlajide, Oludamilolaen_US
dc.contributor.authorMoore, Susanen_US
dc.contributor.authorRaab, Rachelen_US
dc.contributor.authorCarrizosa, Daniel R.en_US
dc.contributor.authorCorso, Stevenen_US
dc.contributor.authorSchwartz, Garryen_US
dc.contributor.authorPeppercorn, Jeffrey M.en_US
dc.contributor.authorEvans, James P.en_US
dc.contributor.authorJones, David R.en_US
dc.contributor.authorDesta, Zeruesenayen_US
dc.contributor.authorFlockhart, David A.en_US
dc.contributor.authorCarey, Lisa A.en_US
dc.contributor.authorIrvin, William J.en_US
dc.date.accessioned2015-11-12T21:03:51Z
dc.date.available2017-01-03T16:21:17Zen
dc.date.issued2015-11en_US
dc.identifier.citationHertz, Daniel L.; Snavely, Anna C.; McLeod, Howard L.; Walko, Christine M.; Ibrahim, Joseph G.; Anderson, Steven; Weck, Karen E.; Magrinat, Gustav; Olajide, Oludamilola; Moore, Susan; Raab, Rachel; Carrizosa, Daniel R.; Corso, Steven; Schwartz, Garry; Peppercorn, Jeffrey M.; Evans, James P.; Jones, David R.; Desta, Zeruesenay; Flockhart, David A.; Carey, Lisa A.; Irvin, William J. (2015). "In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles." British Journal of Clinical Pharmacology 80(5): 1122-1130.en_US
dc.identifier.issn0306-5251en_US
dc.identifier.issn1365-2125en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/115922
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherCYP2D6en_US
dc.subject.otherendoxifenen_US
dc.subject.otherN‐desmethyl‐tamoxifenen_US
dc.subject.otherpharmacogeneticen_US
dc.subject.othertamoxifenen_US
dc.subject.otheractivity scoreen_US
dc.titleIn vivo assessment of the metabolic activity of CYP2D6 diplotypes and allelesen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/115922/1/bcp12665.pdf
dc.identifier.doi10.1111/bcp.12665en_US
dc.identifier.sourceBritish Journal of Clinical Pharmacologyen_US
dc.identifier.citedreferenceBernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: Clinical implications. Oncologist 2006; 11: 126 – 35.en_US
dc.identifier.citedreferenceMeijerman I, Sanderson LM, Smits PH, Beijnen JH, Schellens JH. Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. Drug Metab Rev 2007; 39: 45 – 60.en_US
dc.identifier.citedreferenceBorges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philip S, Nguyen A, Stearns V, Hayes D, Rae JM, Skaar TC, Flockhart DA, Li L. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 2010; 50: 450 – 8.en_US
dc.identifier.citedreferenceGaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234 – 42.en_US
dc.identifier.citedreferenceHicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Muller DJ, Gaedigk A, Stingl JC. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013; 93: 402 – 8.en_US
dc.identifier.citedreferenceCrews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC, Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91: 321 – 6.en_US
dc.identifier.citedreferenceIngelman‐Sundberg M, Daly AK, Nebert DW. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Database 2008; 2010.en_US
dc.identifier.citedreferenceKlein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE. PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics 2013; 23: 643 – 7.en_US
dc.identifier.citedreferenceTeft WA, Gong IY, Dingle B, Potvin K, Younus J, Vandenberg TA, Brackstone M, Perera FE, Choi YH, Zou G, Legan RM, Tirona RG, Kim RB. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat 2013; 139: 95 – 105.en_US
dc.identifier.citedreferenceWang D, Papp AC, Sun X. Functional characterization of CYP2D6 enhancer polymorphisms. Hum Mol Genet 2015; 24: 1556 – 62.en_US
dc.identifier.citedreferenceGaedigk A, Garcia‐Ribera C, Jeong HE, Shin JG, Hernandez‐Sanchez JT. Resolution of a clinical AmpliChip CYP450 Test no call: discovery and characterization of novel CYP2D6*1 haplotypes. Pharmacogenomics 2014; 15: 1175 – 84.en_US
dc.identifier.citedreferenceWang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long‐range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet 2014; 23: 268 – 78.en_US
dc.identifier.citedreferenceAbduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik‐Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther 2010; 88: 643 – 51.en_US
dc.identifier.citedreferenceMuroi Y, Takahashi M, Saito T, Sakuyama K, Niinuma Y, Ito M, Tsukada C, Ohta K, Endo Y, Oda A, Hirasawa N, Hiratsuka M. Functional characterization of wild‐type and 49 CYP2D6 allelic variants for N‐desmethyltamoxifen 4‐hydroxylation activity. Drug Metab Pharmacokinet 2014; 29: 360 – 6.en_US
dc.identifier.citedreferenceMurdter TE, Schroth W, Bacchus‐Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T, Eichelbaum M, Schwab M, Brauch H. Activity levels of Tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011; 89: 708 – 17.en_US
dc.identifier.citedreferenceRelling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89: 464 – 7.en_US
dc.identifier.citedreferenceHicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr Drug Metab 2014; 15: 218 – 32.en_US
dc.identifier.citedreferenceGaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry 2013; 25: 534 – 53.en_US
dc.identifier.citedreferenceIrvin WJ, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, Ogburn ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA. Genotype‐guided tamoxifen dosing increases active metabolite exposure in women with rReduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 2011; 29: 3232 – 9.en_US
dc.identifier.citedreferenceKiyotani K, Mushiroda T, Zembutsu H, Nakamura Y. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. J Hum Genet 2013; 58: 327 – 33.en_US
dc.identifier.citedreferenceProvince MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MM, Ambrosone CB, Beckmann MW, Choi J, Dieudonne A, Fasching PA, Ferraldeschi R, Gong L, Haschke‐Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park B, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin J, Stingl JC, Wegman P, Wingren S, Wu AHB, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE. CYP2D6 genotype and adjuvant tamoxifen: meta‐analysis of heterogeneous study populations. Clin Pharmacol Ther 2013; doi: 10.1038/clpt.2013.186. [Epub ahead of print].en_US
dc.identifier.citedreferenceHertz DL, McLeod HL, Irvin WJ. Tamoxifen and CYP2D6: A contradiction of data. Oncologist 2012; 17: 620 – 30.en_US
dc.identifier.citedreferenceSchroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bolander J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429 – 36.en_US
dc.identifier.citedreferenceGoetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames MM, Ingle JN. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 2013; 19: 500 – 7.en_US
dc.identifier.citedreferenceLeyland‐Jones B, Regan MM, Bouzyk M, Kammler R, Tang W, Pagani O, Maibach R, Dell'Orto P, Thurlimann B, Price KN, Viale G. Outcome According to CYP2D6 Genotype among Postmenopausal Women with Endocrine‐Responsive Early Invasive Breast Cancer Randomized inthe BIG 1–98 Trial. SABCS 2010; General Session 1.en_US
dc.identifier.citedreferenceRegan MM, Leyland‐Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thurlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G. Breast International Group (BIG) 1–98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine‐responsive breast cancer: the Breast International Group 1–98 trial. J Natl Cancer Inst 2012; 104: 441 – 51.en_US
dc.identifier.citedreferenceSaladores P, Murdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, Ganchev B, Eccles B, Gerty S, Tfayli A, Lim JSL, Yap YS, Ng RCH, Wong NS, Dent R, Habbal MZ, Schaeffeler E, Eichelbaum M, Schroth W, Schwab M, Brauch H. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J 2015; 15: 84 – 94.en_US
dc.identifier.citedreferenceMadlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AHB, Pierce JP. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011; 89: 718 – 25.en_US
dc.identifier.citedreferenceDesta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310: 1062 – 75.en_US
dc.identifier.citedreferenceStearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95: 1758 – 64.en_US
dc.identifier.citedreferenceEarly Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient‐level meta‐analysis of randomised trials. Lancet 2011; 378: 771 – 84.en_US
dc.identifier.citedreferenceEarly Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. The Lancet 1998; 351: 1451 – 67.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bcp12665.pdf
Size:
946.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.